1.The Effects of Anticholinesterase Drugs on Gastric Motility.
Hyoung Chul CHOI ; Jong Ho KIM ; Jeoung Hee HA ; Kwang Yoon LEE ; Won Joon KIM ; Dong Suk KWAK ; Sung Hee KIM ; Phil Hyun SONG ; Ji Hyun YEO
Yeungnam University Journal of Medicine 1999;16(2):318-325
BACKGROUND: Anticholinesterase drug inhibits acetylcholinesterase(AChE), induce accumulation of acetylcholine(ACh) near cholinergic receptors and cholinergic stimulation. This experiment was performed to study the effects of anticholinesterase drugs on gastric motility and the effect of ethanal on anticholinesterase drug-induced motility change. MATERIALS AND METHODS: After excision of stomach, 2x10mm circular musele strips were made, which were then fixed to the isolated muscle chamber. An isometric tension transducer was used to measure the contraction change of the gastric smooth muscle strips after drug addition. RESULTS: Fenthion, and irreversible anticholinesterase drug, increased ACh induced contraction of gastric smooth muscle strips and PAM, a cholinesterase activator, antagnized this action. Physostigmine, a reversible anticholinesterase drug, also increased the ACh induced contraction. The gastric motility was decreased by PAM. Ethanol, which is known to induce smooth muscle relaxation, inhibited the increase of contraction by fenthion. CONCLUSION: These results indicate that irreversible and reversible anticholinesterase drugs increase gastric motility and antagonized by cholinesterase activating drugs. And when exposed to both ethanol and anticholinesterase drug, gastric motility was decreased by the smooth muscle relaxation effect by ethanal.
Acetaldehyde
;
Cholinesterase Inhibitors*
;
Cholinesterases
;
Ethanol
;
Fenthion
;
Muscle, Smooth
;
Physostigmine
;
Receptors, Cholinergic
;
Relaxation
;
Stomach
;
Transducers
2.Intermediate Myasthenia Syndrome Following Organophosphate Intoxication.
Jai Woog KO ; Jun Seok PARK ; Kyung Ryung LEE ; Sung Pil CHUNG ; Hahn Shick LEE
Journal of the Korean Society of Emergency Medicine 2000;11(4):579-585
BACKGROUND: Intermediate myasthenia syndrome(IMS) is thought to have clinical importance because it may cause sudden respiratory failure during the recovery phase of a cholinergic crisis of organophosphate poisoning. We designed this study to identify the prevalence, the inducing agent, clinical predictor, and the proposed treatment of IMS. METHODS: Patients who had admitted with the diagnosis of acute organophosphate poisoning from 1992 to 1998 at two teaching hospitals were enrolled in this study. We selected the cases of IMS based on a review of medical records using modified He's criteria. RESULTS: Twelve(12) out of 110 patients with acute organophosphate poisoning were diagnosed for a prevalence at 10.9%. The drug inducing IMS were identified as dichlorvos, fenthion, EPN, methidathion, and phosphamidon. The occurrence of IMS was not related to either the initial treatment with atropine and pralidoxime, or the level of serum cholinesterase. Complications were pneumonia, sepsis, pancreatitis, and pseudomembranous colitis, etc. Eleven(11) patients were discharged without sequelae, and one patient was discharged as a hopeless care. CONCLUSION: This study suggests that IMS is not rare, so close observation is required to detect IMS in organophosphate-poisoning patients. Also, more studies are required to find predictors and treatments.
Atropine
;
Cholinesterases
;
Diagnosis
;
Dichlorvos
;
Enterocolitis, Pseudomembranous
;
Fenthion
;
Hospitals, Teaching
;
Humans
;
Medical Records
;
Organophosphate Poisoning
;
Pancreatitis
;
Phosphamidon
;
Pneumonia
;
Prevalence
;
Respiratory Insufficiency
;
Sepsis